A database of experimental and off-label drugs matched to a patient's disease profile.
Consented intake · your records travel with you · nothing moves without your sign-off
Canti.AI maintains a database for identifying experimental drugs, including off-label options. Using biomarker-drug matching from a patient's test data, it helps surface the treatment options with the most likely effective response. It is for patients who want their search for treatment ideas to reach beyond standard approved uses and into the wider set of drugs being studied.
The fastest way to know what you'll pay: check your coverage with your plan. Below is what we know about how Canti.AI (database to identify experimental drugs, including off-label drugs) handles billing.
We don't have confirmed insurance details for Canti.AI (database to identify experimental drugs, including off-label drugs) yet. Start a coverage check with your plan, or contact the provider directly.
Answers grounded in Canti.AI's details here. Educational only; your oncologist directs treatment.
Powered by Navis on opencancer.ai
Other providers in similar categories.
Identify the best treatment ideas using the best global thinking, predict best treatment response
FoundationOne CDx is an FDA-approved comprehensive genomic profiling test that analyzes 324 genes to identify clinically relevant genomic alterations.
Tempus xT is a comprehensive genomic profiling test combining DNA and RNA sequencing to identify actionable mutations.
Matches your tumor's biomarkers to the therapies most likely to work for you — mapping your molecular profile to targeted and approved options.
This page is general information. Upload your records for analysis specific to YOUR diagnosis.